Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | ATPase family, AAA domain containing 5 | Starlite/ChEMBL | No references |
Homo sapiens | RAB9A, member RAS oncogene family | Starlite/ChEMBL | No references |
Rattus norvegicus | Inositol monophosphatase 1 | Starlite/ChEMBL | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Leishmania major | C-8 sterol isomerase-like protein | 0.0401 | 0.4062 | 1 |
Toxoplasma gondii | inositol(myo)-1(or 4)-monophosphatase 2, putative | 0.0045 | 0.041 | 1 |
Loa Loa (eye worm) | inositol-1 | 0.0045 | 0.041 | 0.0415 |
Trichomonas vaginalis | myo inositol monophosphatase, putative | 0.0045 | 0.041 | 1 |
Wolbachia endosymbiont of Brugia malayi | fructose-1,6-bisphosphatase | 0.0045 | 0.041 | 0.5 |
Brugia malayi | Inositol-1 | 0.0045 | 0.041 | 0.0415 |
Brugia malayi | ERG2 and Sigma1 receptor like protein | 0.0401 | 0.4062 | 0.4118 |
Echinococcus multilocularis | inositol monophosphatase 1 | 0.0045 | 0.041 | 0.041 |
Loa Loa (eye worm) | hypothetical protein | 0.0205 | 0.2053 | 0.2081 |
Trypanosoma brucei | C-8 sterol isomerase, putative | 0.0401 | 0.4062 | 1 |
Chlamydia trachomatis | 3'(2'),5'-bisphosphate nucleotidase CysQ | 0.0005 | 0 | 0.5 |
Entamoeba histolytica | myo-inositol monophosphatase, putative | 0.0045 | 0.041 | 1 |
Mycobacterium leprae | possible inositol monophosphatase SubH (IMPase) (inositol-1-phosphatase) (I-1-Pase ). | 0.004 | 0.0362 | 1 |
Echinococcus granulosus | vesicular acetylcholine transporter | 0.0966 | 0.9863 | 1 |
Schistosoma mansoni | vesicular acetylcholine transporter | 0.0966 | 0.9863 | 1 |
Echinococcus multilocularis | vesicular acetylcholine transporter | 0.0966 | 0.9863 | 0.9863 |
Echinococcus granulosus | inositol monophosphatase 1 | 0.0045 | 0.041 | 0.0415 |
Mycobacterium tuberculosis | Inositol-1-monophosphatase SuhB | 0.004 | 0.0362 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0401 | 0.4062 | 0.4118 |
Trichomonas vaginalis | inositol monophosphatase, putative | 0.0045 | 0.041 | 1 |
Mycobacterium ulcerans | extragenic suppressor protein SuhB | 0.0045 | 0.041 | 1 |
Trichomonas vaginalis | myo inositol monophosphatase, putative | 0.0045 | 0.041 | 1 |
Schistosoma mansoni | inositol monophosphatase | 0.0045 | 0.041 | 0.0415 |
Loa Loa (eye worm) | vesicular acetylcholine transporter unc-17 | 0.0966 | 0.9863 | 1 |
Trypanosoma cruzi | myo-inositol-1(or 4)-monophosphatase 1, putative | 0.0045 | 0.041 | 0.1009 |
Onchocerca volvulus | Vesicular acetylcholine transporter homolog | 0.0966 | 0.9863 | 1 |
Trypanosoma brucei | inositol-1(or 4)-monophosphatase 1, putative | 0.0045 | 0.041 | 0.1009 |
Trypanosoma cruzi | myo-inositol-1(or 4)-monophosphatase 1, putative | 0.0045 | 0.041 | 0.1009 |
Brugia malayi | vesicular acetylcholine transporter unc-17 | 0.0966 | 0.9863 | 1 |
Leishmania major | myo-inositol-1(or 4)-monophosphatase 1, putative | 0.0045 | 0.041 | 0.1009 |
Schistosoma mansoni | inositol monophosphatase | 0.0045 | 0.041 | 0.0415 |
Giardia lamblia | Hypothetical protein | 0.0005 | 0 | 0.5 |
Trypanosoma cruzi | C-8 sterol isomerase, putative | 0.0401 | 0.4062 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 1.6511 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | = 6.3096 um | PUBCHEM_BIOASSAY: qHTS Assay for Rab9 Promoter Activators. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 8.9125 um | PUBCHEM_BIOASSAY: qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium. (Class of assay: confirmatory) [Related pubchem assays: 901 ] | ChEMBL. | No reference |
Potency (functional) | 16.3601 uM | PUBCHEM_BIOASSAY: qHTS screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493106, AID493143] | ChEMBL. | No reference |
Potency (functional) | 20.5962 uM | PUBCHEM_BIOASSAY: qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493107, AID493125] | ChEMBL. | No reference |
Potency (functional) | 26.8545 uM | PUBCHEM_BIOASSAY: qHTS profiling assay for firefly luciferase inhibitor/activator using purified enzyme and Km concentrations of substrates (counterscreen for miR-21 project). (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID2288, AID2289, AID2598, AID411] | ChEMBL. | No reference |
Potency (binding) | = 28.1838 um | PUBCHEM_BIOASSAY: qHTS Assay for Identification of Novel General Anesthetics. In this assay, a GABAergic mimetic model system, apoferritin and a profluorescent 1-aminoanthracene ligand (1-AMA), was used to construct a competitive binding assay for identification of novel general anesthetics (Class of assay: confirmatory) [Related pubchem assays: 2385 (Probe Development Summary for Identification of Novel General Anesthetics), 2323 (Validation apoferritin assay run on SigmaAldrich LOPAC1280 collection)] | ChEMBL. | No reference |
Potency (functional) | = 39.8107 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1). (Class of assay: confirmatory) [Related pubchem assays: 1030 (qHTS Validation Assay for Inhibitors of aldehyde dehydrogenase 1 (ALDH1A1))] | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of BAZ2B. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504391] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.